ImCheck Presents at SITC First Clinical Demonstration of Gamma Delta T Cell Activation and Tumor Infiltration with Positive Safety for ICT01
November 11, 2020 07:00 ET
|
ImCheck Therapeutics SAS
ImCheck Presents at SITC First Clinical Demonstration of Gamma Delta T Cell Activation and Tumor Infiltration with Positive Safety for ICT01 Preliminary EVICTION Phase I/IIa trial data shows...
Checkpoint Therapeutics Announces Presentation of Updated Cosibelimab Lung Cancer Results at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
November 09, 2020 08:00 ET
|
Checkpoint Therapeutics, Inc
44.0% objective response rate and 10.3-month median progression-free survival observed in non-small cell lung cancer (NSCLC) cohortPhase 3 registration-enabling trial planned in first-line metastatic...
BioNTech to Present Data from BNT311 (GEN1046) and BNT131 (SAR441000) Programs at SITC 35th Annual Meeting
October 14, 2020 17:00 ET
|
BioNTech SE
Data updates from key oncology collaborations to be presentedPreliminary data from the first-in-human trial from intratumoral immunotherapy program BNT131 (SAR441000) in collaboration with Sanofi, to...
Vaccinex Announces Three Oral Presentations Highlighting Semaphorin 4D (SEMA4D) at the ASCO-SITC Clinical Immuno-Oncology Symposium
February 06, 2020 07:31 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...
Vaccinex Reports Third Quarter 2019 Financial Results and Provides Corporate Update
November 12, 2019 08:00 ET
|
Vaccinex, Inc.
Completed enrollment of the dose expansion cohort in the Phase 1b/2 CLASSICAL-Lung study in non-small cell lung cancer; primary completion expected by the end of 2019 Updated interim data from the...
Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
November 09, 2019 08:02 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Nov. 09, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...
Autolus Therapeutics Presents Preclinical Data on AUT06NG at the SITC Annual Meeting
November 09, 2019 07:00 ET
|
Autolus Therapeutics plc
LONDON, Nov. 09, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment...
Bellicum Pharmaceuticals Presents Encouraging Preclinical Data for GoCAR-NK Cell Program at Society for Immunotherapy of Cancer Annual Meeting
November 08, 2019 07:00 ET
|
Bellicum Pharmaceuticals, Inc.
iMC activation enhances innate NK cell cytotoxicity against tumor cell lines in vitro MC activity enhances the efficacy of CAR-NK cells against hematological and solid tumor models MC signaling...
Jounce Therapeutics Reports Third Quarter 2019 Financial Results
November 07, 2019 06:30 ET
|
Jounce Therapeutics, Inc.
- New safety and preliminary efficacy data from JTX-4014 to be presented at the SITC 2019 Annual Meeting - - JTX-4014 data supports use as a combination agent for future studies - - 2019 cash...
Jounce Therapeutics to Present Safety and Preliminary Efficacy Data on JTX-4014 and a Trials in Progress Poster for the Vopratelimab EMERGE Study at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting
November 05, 2019 08:05 ET
|
Jounce Therapeutics, Inc.
- Recommended Phase 2 dose determined for future JTX-4014 trials - - Introducing the dosing and sequencing strategy for vopratelimab and ipilimumab in ongoing EMERGE Phase 2 trial - CAMBRIDGE,...